HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pending FDA User-Fee Legislation May Be ‘Big Shot’ For Cosmetics Reg Reform

This article was originally published in The Rose Sheet

Executive Summary

The Personal Care Products Council expects at least three cosmetics reform bills to make reappearances in the 115th Congress, but the best opportunity for updating regulations may involve tacking related provisions onto must-pass FDA user-fee bills this year. Top execs discussed the current legislative landscape during the “Washington Report” session of the trade group’s annual meeting in Palm Beach, Fla.

You may also be interested in...

Cosmetics Reg Reform Ill-Situated As Trump, FDA Explore 'Burden Reduction'

Any movement to advance proposed cosmetics reform legislation could be seen as running counter to President Trump's executive orders earlier this year, which now have FDA centers seeking "broad public comment" on how to achieve "meaningful burden reduction."

ICMAD Broadens Advocacy Focus With Cosmetics Reform A Low Priority In Congress

Legislation to update cosmetics regulations may not have legs in the 115th Congress, but the Independent Cosmetic Manufacturers and Distributors will have an active presence on Capitol Hill regardless. President and CEO Pam Busiek says the small-business trade group will continue working to educate lawmakers on regulatory reform issues while expanding its advocacy work to address tax and trade concerns.

Cosmetics Provisions Unlikely To Catch Ride On FDA User-Fee Bill

With the release of an atypically lean, clean FDA user-fee reauthorization draft bill, it’s doubtful that cosmetics regulatory reform language will get tacked onto the must-pass legislation. Stakeholders likely will refocus their efforts on standalone cosmetics legislation to modernize FDA’s oversight of the industry.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts